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Abstract 
Background 
Liver function tests (LFTs) are commonly abnormal, most patients with ‘incidental’ abnormal LFTs are 
not investigated appropriately and for those that are, current care pathways are geared to find an 
explanation for the abnormality by a lengthy process of investigation and exclusion, with costs to the 
patient and to the health service. 
Objective:  
To validate an intelligent automatable analysis tool (iLFT) for abnormal liver enzymes, which diagnoses 
common liver conditions, provides fibrosis stage and recommends management  
Design:  
A retrospective case note review from three tertiary referral liver centres, with application of the iLFT 
algorithm and comparison to the clinician’s final opinion as gold standard.  
Results: 
The iLFT algorithm in 91.3% of cases would have correctly recommended referral or management in 
primary care. In the majority of the rest of the cases,  iLFT failed safe and recommended referral even 
when the final clinical diagnosis could have been managed in primary care. Diagnostic accuracy was 
achieved in 82.4% of cases, consistent with the failsafe design of the algorithm. Two cases would have 
remained in primary care as per the algorithm outcome, however on clinical review had features of 
advanced fibrosis.  
Conclusion: 
iLFT analysis of abnormal liver enzymes offers a safe and robust method of risk stratifying patients to 
the most appropriate care pathway as well as providing reliable diagnostic information based on a 
single blood draw, without repeated contacts with health services. Offer the possibility of high quality 
investigation and diagnosis to all patients rather than a tiny minority. 
Summary Box: 
What is already known about this subject? 
• Currently, there is significant heterogeneity in the handling and analysis of deranged liver 
enzymes  
• This creates uncertainty, unnecessary investigations and delays in diagnosis 
• There is also an associated cost burden with the current system of liver enzyme assessment 
What are the new findings? 
• This novel automated approach streamlines the analysis and subsequent investigation of 
deranged liver enzymes, providing a structured methodical approach 
• Employing non-invasive fibrosis scores allows safe identification of patients with more 
advanced liver disease 
• This structured automated approach demystifies liver enzyme derangement for the primary 
care provider 
How might this impact on clinical practice in the foreseeable future? 
A structured and automated analysis of deranged liver enzymes streamlines patient investigations and 
referrals, with the potential impact of a higher, earlier rate of detection of liver disease. There is the 
potential for significant cost savings in the patient journey without compromise on patient safety 
 
 
 
Background 
There has been a dramatic increase in the number of liver function tests (LFTs) requested in both 
primary and secondary care. The majority of tests are requested in connection with exploring 
undifferentiated illness, and monitoring non-hepatic long term health conditions, particularly those 
related to cardio-vascular risk factor reduction. LFTs are often the gateway to further invasive and/or 
expensive investigations. It can be unclear whether an initial abnormal LFT(1) might signify current or 
future liver disease,  significant disease in other organs, or may be a temporary phenomenon of little 
clinical relevance. However what is clear is that in around 20% of initial LFTs, one or more of the 
enzyme levels are abnormal (1). The next stage of diagnostic tests such as ultrasound, although not 
‘invasive’, draws many well people or those without liver disease into hospital hepatology 
investigation pathways, whilst leaving many abnormal LFTs unexplained. Newer non-invasive 
approaches such as the “ELF test”(2) are being evaluated to help diagnose fibrotic liver disease, but 
have yet to find their place in the diagnostic pathway. Guidelines for primary care have been published 
for evaluation of abnormal LFT’s in asymptomatic patients but did not cover further testing nor take 
account of costs to the patient or the health service (3). Additionally research shows that few of these 
recommendations are followed in accordance with best practice standards. Tapper et al (4) assessed 
the cost effectiveness of a directed approach to investigating elevated ALT compared with a non-
directed approach, whereby a full liver panel was performed on the first abnormal ALT detection. They 
found the non-directed approach to be more cost effective and provide one additional diagnosis per 
100 compared with the directed approach, at the expense however of a higher false positive rate. 
Furthermore when they modelled the effect of different population prevalence’s of Nonalcoholic Fatty 
Liver Disease (NAFLD), Alcohol Related Liver Disease (ARLD) and Drug Induced Liver Injury (DILI) they 
found that the directed approach became more cost effective at prevalence’s above 53%, 51.1% and 
13% respectively, rates higher than the general population prevalence.  
This increase in testing occurs in the context of the prevalence and mortality from chronic liver disease 
rising rapidly in the last few decades. In the United Kingdom liver disease is the only major disease 
area with an increasing death rate in those under 65 and is now the third most common cause of death 
in men of this age.  The commonest causes of abnormal LFTs leading to chronic liver disease are 
NAFLD(5), ARLD (6) and hepatitis C virus infection (HCV) (7). These conditions are becoming more 
prevalent and pose a considerable burden on the health service (8). However there are many other 
causes of abnormal LFTs including biliary disease, drug reactions, reactions to systemic illness and 
hepatic infections. Despite the increasing testing of LFTs, patients continue to present with 
undiagnosed end stage liver disease, which may have been preventable by earlier diagnosis. These 
include: autoimmune hepatitis which is responsive to steroids, hepatitis C infection which can be 
cured in most patients by antiviral drugs, and alcohol misuse, where brief interventions may be 
effective (9). The LFT abnormalities may also be consequent on serious disease elsewhere requiring 
treatment, such as malignancy where its early detection may improve the prognosis.   
The Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS) study found fewer than 
5% of cases with abnormal liver enzymes had a specific liver condition, either chronic or acute and 
only 1.3% of cases had a serious liver condition (10). The ALFIE study, a population-based study found 
abnormal liver enzymes can be detected in over 21% of the population, with only 1.14% developing 
liver disease over a medium term follow up (1). The majority of the remaining LFT abnormalities being 
attributable to hepatic steatosis of various aetiologies or hepatic reactions to systemic illness. The one 
caveat to these large studies is that they do not have the prolonged follow up that is required to 
explore the natural history of chronic liver disease. 
Interpretation of abnormal LFT’s remains challenging, especially so in a primary care setting where co-
morbidity and high workload makes focusing on single condition clinical pathways unrealistic. The 
obesity epidemic and historically high rates of alcohol consumption, are likely to result in an increase 
in the discovery of abnormal LFT’s (11). The anticipated burden of work is such that it may be expected 
that primary care will be inundated with patients concerned about whether they have liver disease, 
and secondary care services inundated with referrals. There is a pressing need to risk stratify 
individuals with abnormal LFT’s, allowing safe and effective triage, thus optimising access and 
efficiency of secondary care services.  
To date diagnostic algorithms for LFTs have attempted to diagnose everyone, in cycles of repeated 
testing of the LFTs with progressive adding of further more complex tests. An alternative approach is 
not to try to diagnose everyone but to identify those patients that can classified easily and triaged. To 
do this we defined a minimum diagnostic criteria that allowed the diagnosis and prognosis of a liver 
disease and classification into three groups:   
a) Those with liver disease that was simple and at early stage that could be managed in general 
practice, for example alcohol related fatty liver disease.  
b) Those with complex or advanced disease that require secondary care management or further 
diagnostic input from secondary care, for example suspected auto-immune liver disease.  
c) those without a clear diagnosis, negative screens for liver disease who would be managed by the 
GP initially reviewing available results in the patient specific context and planning further 
management according as is the current standard pathway.  
Such criteria could be incorporated into an automated blood sciences laboratory management system, 
which would allow input of the additional clinical information, automated triggering of the additional 
blood tests and staging calculations, if abnormal LFTs were detected on the original patient sample. 
Finally the diagnostic information and automated interpretation could be returned to the GP 
electronically removing many steps of visits and repeated testing, for efficient management.  
 
Aims 
1) To describe the process of development of triage criteria. 
2) To validate the criteria in a large real world cohort of patients.   
 
Method 
Development of criteria 
An expert group of  5 Hepatologists met, on several occasions, using Delphi methodology(12). 
They were tasked with defining objective criteria to allow a confident diagnosis of common liver 
diseases based on a limited number of parameters. Specifically, the criteria were not required to 
diagnose everyone with a disease and had to be based on a limited information set without clinical 
examination. Patients with overt jaundice were excluded and it was also assumed that any derived 
diagnosis would be advisory and reviewed by a practitioner when the result of an abdominal 
ultrasound became available later. 
The available information set was: 
• Patient specific factors; age, sex, Body Mass Index (BMI), features of the metabolic syndrome and 
alcohol intake  
• The results of a liver disease aetiology screen; hepatitis serology, liver immunology, ferritin, alpha-
1-antitrypsin and caeruloplasmin,  
• Fibrosis staging; FIB4 and the NAFLD fibrosis score.  
The criteria employed assessment of liver fibrosis by means of non-invasive fibrosis panels, in 
order to risk stratify cases. The NAFLD Fibrosis Score was used for cases where NAFLD was the 
suspected diagnosis (13). All cases scoring > -1.455 (i.e. indeterminate cases as well as cases of F3/4) 
were recommended for referral. For all other liver conditions both FIB4 (14) and APRI (15) were used. 
If both or either suggested indeterminate or advanced fibrosis, referral was recommended.  
The expert panel agreed a list of common and or important liver diseases (see Table 1) for 
each disease or disease stage, each panellist using the available information, defined combinations 
which allowed confident diagnosis of the condition. These were collated and all results were feed back 
to the experts, with conflicts of opinion and reasoning for them shared. Additionally at this stage 
mutual exclusivity was checked between the diagnostic criteria and overlaps feed back to the experts. 
The responses were collated and the criteria used on a consecutive series of referrals to a liver clinic 
for abnormal LFTs. The collated criteria and performance in the case note series was feed back to the 
experts and consensus was achieved.    
  
 Table 1: Diagnostic criteria agreed for each liver disease, or stage of liver disease 
Diagnosis Diagnostic criteria Management  
Primary Biliary 
Cholangitis (PBC) 
Increased Alkaline phosphatase,  Positive 
AMA 
Referral  to secondary care 
Autoimmune 
Hepatitis (AIH) 
 
ALT increased, Positive ANA Positive ASMA 
>1:80. 
Referral to secondary care 
Hepatitis C 
infection (HCV) 
HCV antibody positive.  
Perform PCR or HCV ag by local preference. 
Referral for HCV treatment, if HCV PCR of HCV Ag positive. 
 
Hepatitis B 
Infection (HBV) 
HBsAg positive  Refer to HBV services  
Haemochromatosis 
 
Both ferritin and transferrin saturation 
increased above local normal ranges 
Referral for genetic confirmation and venesection. 
 
Wilsons 
 
Caeruloplasmin abnormal (<0.47g/L). (only 
performed aged less than 55)  
Referral to secondary care 
Alpha 1 antitrypsin 
deficiency 
Low level A1AT (<0.9g/L) Referral to secondary care 
NAFLD simple 
steatosis 
 
 
ALT and/or GGT elevated, all above tests 
normal, alcohol intake less than 14 units* 
per week. 
NAFLD Fibrosis score low (< -1.455) 
Primary care, screen for diabetes, address cardiovascular risk factors, perform 
abdominal ultrasound if no abnormality other than increased echogenicity then 
manage  repeat NAFLD Fibrosis score annually 
NAFLD- NASH with 
significant fibrosis 
 
Above tests normal drink less than 14 units 
per week.   
NAFLD Fibrosis score high or indeterminate 
(>-1.455) 
Refer secondary care for assessment of liver fibrosis.  
ARLD with no / 
minimal fibrosis  
Above tests normal (1+ASMA allowed), 
drinking in excess of 14 units per week 
 AST/ALT ratio (<0.8), APRI score (<0.5) or 
FIB-4 (1.45)  all low 
Management in primary care, Advise abstinence perform Alcohol brief 
intervention. Onward referral to alcohol problems services depending on local 
guidelines.  
ARLD with 
indeterminate or 
high fibrosis score 
Liver screen tests negative (1+ASMA 
allowed), drinking in excess of 14. 
AST/ALT ratio (>1.0), APRI (>0.5) score or 
FIB-4 (>1.45) elevated or abnormal bilirubin 
albumin or clotting. 
Refer to secondary care for staging 
Isolated Elevated 
Alkaline 
Phosphatase, 
normal GGT, tests above normal Unlikely to be liver disease Consider systemic disease causing abnormality 
especially skeletal causes e.g. pregnancy, fractures, Paget’s, growing child,. In 
Primary care consider abdominal U/S, 
Gilberts 
 
 
Isolated elevated Bilirubin,  If less than 45 µmol/l in non-fasting/dieting state. Reassurance in primary care. If 
>45µmol/l check for haemolysis and genetic testing for Gilberts. If both negative 
consider referral 
Drug reaction 
 
 
 
None of the above criteria for filled, check if 
prescribed potentially hepatotoxic drug in 
the 3 months preceding first abnormal LFT. 
Can check using { HYPERLINK 
"http://www.livertox.nlm.nih.gov/" } . 
In primary care if clear Drug Induced Liver Injury stop drug and repeat LFTs, 
normalisation over 6-8 weeks confirms diagnosis. NB elevations less than 5x ULN 
occurring with initiation of statins is common and safe, not requiring stopping of 
the drug. 
Other diseases or 
atypical 
presentations 
None of the above positive In primary care consider requesting abdominal U/S. Consider systemic disease 
causing abnormal LFTs. Repeat LFTs in 3 months, if abnormality persists, in the 
absence of explanation consider referral depending on the clinical context of the 
patient and risk scores for age standardised mortality.  
*unit of alcohol is 10ml (8g) of pure alcohol) 
  
 For some conditions, a clear and definitive diagnostic test exists (i.e. HCV). For other conditions a more 
detailed biochemical, virological and immunological panel, either positive or negative, is required 
before a diagnosis can be reached. Criteria were set in such a way that in scenarios where there were 
unlikely diagnoses but with very different treatment or prognosis then the criteria would trigger 
referral. Such scenarios are most common in patients with alcohol related fatty liver disease (ARFLD) 
or NAFLD with simple steatosis who have positive liver immunology, raising the rare but important 
possibility that they have autoimmune liver disease. In these cases the criteria would allocate a 
possible diagnosis of autoimmune disease which would trigger referral to secondary care for expert 
assessment. This policy of diagnostic “fail safe” was built into all the criteria. HCV, HBV and 
autoimmune liver conditions or NAFLD and ARFLD with indeterminate or elevated fibrosis staging 
were considered for referral to specialist services. NAFLD and ARFLD with low (F0-2) non-invasive 
fibrosis scores were recommended for management in Primary Care. The group where a diagnosis 
cannot be made robustly; comprises in the main patients with NAFLD who do not have overt obesity 
or other features of the metabolic syndrome, those in whom history of alcohol excess was not initially 
discovered, unusual liver diseases and those with systemic illness and or a non-liver cause of elevation 
of an LFT analyte. These cases are highlighted for GP review in the same manner as is current practice 
but with a much reduced likelihood of parenchymal liver disease. All recommendations were 
provisional on the result of abdominal ultrasound scanning. Information sheets for GP’s were 
produced for each of the liver conditions with brief descriptions of the condition, recommendations 
for the next investigation and management steps as well as the referral recommendation.  
Validation of criteria 
The criteria for diagnosis were validated against a retrospective case note validation study of 
consecutive new patient referrals with abnormal LFTs to the liver services at three tertiary referral 
centres. Patients with focal lesions, patients with known imaging demonstrating a dilated biliary tree, 
patients referred for management of a diagnosed liver disease and patients with jaundice were 
excluded.  A researcher extracted data for the minimum diagnostic criteria and the final diagnosis and 
outcome of the referral, using the hospital liver clinicians’ opinion as the gold standard for diagnosis. 
The criteria based diagnosis and the referral recommendation were compared to the clinician’s 
diagnosis. The accuracy of the pathway was assessed based on the number of correct diagnoses and 
referral decisions using the algorithm and against the final “fail safe criteria” of all recommendations 
for primary care management. We examined in detail all cases of diagnostic disagreement, with 
particular focus on cases where the automated process suggested primary care management when 
specialist referral and review was warranted.  
 
Results 
 A total number of 378 cases were included in the validation cohort for the study. Fifty-five cases were 
found to be jaundiced (bilirubin >/= 22, range 22-117) and therefore removed from the analysis. Thus, 
323 cases were included. Table 2 shows the demographics of cohort studied.  
Table2: Demographics and frequency of diagnoses for the entire cohort, as well as by site   
  Entire cohort Dundee Aberdeen Glasgow 
n=  323 190 41 92 
Age  53.4 57 54 49.3 
%female  49.5% 53% 54% 41% 
BMI  29.9 30.3 29.5 29.4 
Diagnosis:       
 PBC 19 18 1 0 
 AIH 19 17 2 0 
 HCV 48 4 1* 43* 
 HBV 9  6* 3* 
 Haemochromatosis 12 6 2 4 
 Wilson's 0 0 0 0 
 A1AT 4 4 0 0 
 NAFLD, no fibrosis 78 60 8 10 
 NAFLD with fibrosis 37 21 8 8 
 ARLD, no fibrosis 21 16 2 3 
 ARLD with fibrosis 24 8 1 15 
 
Isolated elevated Alk 
Phos 10 7 0 3 
 Gilbert's 0 0 0 0 
 DILI 8 8 0 0 
 Unclear 34 21 10 3 
*1 case of HBV/HCV co-infected 
Diagnostic agreement 
 There was agreement in the diagnosis reached with the automated pathway in 82.4% of cases 
(n=266). In all of these cases, the appropriate referral option would have been selected by the 
automated process. 168 cases were allocated to the Refer to secondary care group (52% of the entire 
cohort) and 98 cases were allocated to the Manage in GP group (30.3% of the entire cohort).  
Diagnostic disagreement 
There was diagnostic disagreement between the automated pathway and the responsible clinician in 
17.6% of the cases assessed. Of those 57 cases, 29 cases would have been referred to secondary care. 
Despite the incorrect diagnosis, 12 of those 29 cases required a secondary care opinion. The remaining 
17 cases did not require a secondary care opinion.  
The majority of cases had underlying alcohol related or NAFLD, with positive auto-antibodies, elevated 
ferritins, elevated fibrosis scores or borderline low alpha 1-anti-trypsin levels so the criteria performed 
as they were designed to do and failed safe, suggesting a possible diagnosis that would require 
secondary care opinion to investigate or exclude.  
Figure 1 describes the cases of diagnostic agreement and disagreement, as well as the ultimate referral 
destination. Table 3 describes by disease aetiology where there was agreement and disagreement 
between the automated process and the clinical diagnosis 
Figure 1: Diagnostic agreement between the automated process and the clinical diagnosis 
Table 3: Diagnostic agreement / disagreement for the various aetiologies encountered with clinical 
opinion at clinical review as gold standard 
 
Diagnostic 
Agreement 
Diagnostic 
disagreement 
n= 266 57 
   
PBC 17 2 
AIH 4 14 
HCV 46 0 
HBV 8 0 
HFE 14 1 
Wilson's 0 0 
A1AT 0 4 
NAFLD, no fibrosis 90 16 
NAFLD with fibrosis 10 3 
ARLD, no fibrosis 20 4 
ARLD with fibrosis 12 0 
Isolated elevated ALP 6 4 
Gilbert's 0 0 
DILI 11 0 
Unclear 28 9 
 
 
 
Referral recommendation 
The correct referral pathway was selected in 295 cases (91.3%) of cases, regardless of the accuracy of 
the final diagnosis. There were 28 cases where the referral pathway was not appropriate (8.6%). Figure 
2 describes the referral recommendation accuracy, showing the number of patients referred to the 
correct destination (primary or secondary care). 
Figure 2: Referral pathway recommendations. 
 
Using the ultimate referral decision, rather than the actual diagnosis, the automated intervention has 
a sensitivity of 94.3% and a specificity of 86%. 
 Twenty eight cases would have remained in primary care, 23 appropriately despite an 
incorrect diagnosis. Five cases (1.5% of the total cohort) would have remained in primary care, 
however required a secondary care referral.  
1. One case had an ultimate diagnosis of Varicella zoster related enzyme derangement – the 
automated process recorded a diagnosis of ARLD with no evidence of significant fibrosis.  
2. A case of acute HEV was misclassified as NAFLD with normal fibrosis scores. – the protocol for 
NAFLD diagnosis uses an upper limit of 300 IU/L for NAFLD. At the time of referral this patient 
had an ALT below 300.   
3. A case with features of the metabolic syndrome, an ALT of 91 U/L and a negative liver screen. 
The NAFLD Score was -1.52 (low risk). The criteria suggested a diagnosis of NAFLD with no 
evidence of significant fibrosis. At clinical review a Fibroscan was elevated and the patient 
subsequently diagnosed with NASH related cirrhosis.  
4. A case of portal, splenic and SMV thrombosis was classified as NAFLD with normal fibrosis 
scores.  
5. A case of ARLD related cirrhosis was classified as ARLD with normal fibrosis scores, as the FIB4 
value was calculated at 1.31. However, upon clinic review the patient had evidence of portal 
hypertension. 
Of the cases that were misallocated, two (the HEV and Varicella zoster) are self-limiting usually and if 
the algorithm had been used on diagnosis bloods rather than clinic bloods when the transaminitis had 
resolved, they would have been correctly allocated.  The portal vein thrombosis would have been 
picked up on the abdominal ultrasound examination that would still be part of the evaluation of these 
patients. The 2 patients with cirrhosis not detected by the fibrosis markers reflects the known fail rate 
for these tests and needs to be viewed in terms of missing many more patients if no tests were done. 
Potential Impact 
Of the 323 cases in the study all of whom had been referred to secondary care 116 (35.9%) would 
have been manged in primary care with the use of the criteria. The majority of these cases were either 
NAFLD or ARLD with low non-invasive fibrosis markers, requiring life style advice about diet and 
exercise or an alcohol brief intervention, all of which should have been provided in primary care after 
the secondary care intervention, anyway so would not be associated with extra workload. This is 
already a population selected for referral so a higher proportion of primary care management would 
be expected in an unselected population. A proportion of those classed as requiring secondary care 
intervention was on the basis of indeterminate values from non-invasive fibrosis assessment methods. 
The use of advanced fibrosis markers such as the ELF panel or direct access to liver stiffness 
measurement could further reduce referral.  
Discussion 
Only a fraction of individuals in with abnormal liver enzymes detected in primary care, go on to 
develop significant liver disease in medium term follow up.  In some studies this is as low as 1.4-5% (1, 
16), but despite this, as a result of the vast number of tests performed, this still represents a huge 
impact on public health. The intelligent use of healthcare resources described here could allow 
appropriate referral and triage of patients at greatest risk of significant liver disease, whilst 
simultaneously providing additional support and information to primary care givers for those patients 
at less risk.  
A problem with the assessment of abnormal LFTs is that for many patients the consideration of 
multiple factors by an expert in liver disease is required to arrive at a diagnosis. This has lent an “air 
of mystique” to the diagnosis of liver disease. This study shows this need not be the case: many 
patients can be triaged simply and effectively at point of first presentation of abnormal LFTs. This   
decision support tool for GPs and the 20% of their patients who have abnormal LFTs tested for a 
variety of reasons(1), could transform the management. Further work is needed to quantify just how 
significant an impact this could have on patients, primary and secondary care services.  
The project described here arose from a working group convened by the Scottish Government. The 
Liver Care Pathway Advisory Group focussed on the problem of late presentation of liver disease with 
tragic consequences and the difficulties of spotting liver disease early among all the patients with 
abnormal LFTs.  The project has used an extensive literature review and expert opinion to achieve 
professional consensus on minimum diagnostic criteria for liver diseases. The criteria define the liver 
diseases of interest and define the general practice role in each diagnostic group, i.e. therapeutic 
management within primary care or referral for specialist management. In essence, for each liver 
disease a set of highly specific diagnostic criteria have been identified based on a few simple clinical 
observations and blood test results. This allows diagnosis using a minimal number and values of 
diagnostic criteria that gives confidence that those identified do have the disease, and accepts that 
others might have the disease but does not attempt to be all inclusive. These criteria allow patients to 
be allocated to one of 3 groups:  those that have serious or complex disease that requires secondary 
care management, those that have less serious disease that can be managed within primary care and 
those in whom the diagnosis is not clear. This study investigated the utility of this approach to the 
diagnosis of liver disease compared to conventional services, clearly it has demonstrated that the 
algorithm functioned well in this unselected cohort of secondary care referrals.  
The criteria and algorithm described in this study could streamline practice in relation to 
abnormal liver enzymes, reducing delays and associated costs to performing second line investigations 
(a liver disease aetiology screen). We have shown the algorithm to be robust and risk averse, ensuring 
those with markers of alternative diseases or indeterminate fibrosis markers are still referred for 
secondary care opinion or investigation. If this process was automated, which it lends itself to, it could 
reduce contact time and episodes in general practice and reducing the burden of potential referrals 
to secondary care clinics.  
The system makes extensive use of fibrosis scoring algorithms to stage patients liver disease, these 
include the NAFLD fibrosis score, APRI and FIB4. The NAFLD Fibrosis Score (NAFLD FS) is widely used 
in secondary care settings, with many units using the score to risk stratify patients with NAFLD(13). 
Furthermore, a NAFLD FS of intermediate or high at presentation is associated with a significant risk 
of liver events and mortality with a hazard ratio of 7.7 and 34.2 respectively (13).  In this project 
NAFLD FS has been used to risk stratify NAFLD patients. Those with low scores are recommended for 
primary care management, those with indeterminate or high scores, are recommended for referral 
for further staging tests such as liver stiffness measurement or biopsy. One potential weakness of 
this approach is the long term follow up of these patients. There is no evidence to support the serial 
measurement of the NAFLD FS in order to detect the development of fibrosis. Pragmatically, we 
advise the primary care giver to prescribe lifestyle intervention measures and repeat the NAFLD FS 
on annual basis. For other aetiologies of liver disease, APRI (15) and FIB4 (14) are well validated non-
invasive fibrosis assessing tools. Serum based non invasive fibrosis detection algorithms have 
limitations. They perform well at detection of advanced disease, however are not infallible and should 
be interpreted accordingly .Erring on the side of caution we suggested the measurement of both for 
all liver conditions other than NAFLD. If either APRI or FIB4 did not suggest minimal fibrosis, referral 
was suggested. Within our study cohort, this occurred in fewer than 5 cases. This combined use of 
the two distinct tools is novel and pragmatic, with a failsafe approach in mind. AUSS is useful in the 
detection of fatty infiltration of the liver as well as lesion detection (including gallstones), however has 
a limited role in the diagnosis of autoimmune and viral liver conditions – its role in this setting is an 
exclusionary one. 
 
The overall accuracy of patient allocation to secondary care referral or primary care follow up 
was very high. The diagnosis accuracy was less good but this is an artificial effect reflecting the 
intention and design of the diagnostic criteria to fail safe. The majority of the apparent incorrect 
diagnosis from the criteria, is due to either the possibility of auto-immune liver disease because of 
positive anti-smooth muscle antibodies in patients with ARLD or NAFLD or patients with elevated 
fibrosis scores requiring further secondary care investigation to define the degree of fibrosis. New 
more accurate blood tests for fibrosis, for instance ELF are not routinely available to general practice 
and fibroelastography is not currently available directly to primary care. Increased availability of either 
of these technologies could further reduce the need for referral. 
These diagnostic criteria can be applied by clinicians to patients in the run of a clinical 
consultation and they would be an aid to accurate and efficient diagnosis. However they were 
designed to enable automated management. Technological developments within blood science 
laboratories have led to computerised test ordering and communications systems and the use of 
tracked analysers where patient samples are passed between analysers using micro rail systems, 
which are computer controlled. This means that in real time the system can change a sample’s journey 
based on the preceding results for that sample. A new care pathway could be developed from the 
diagnostic criteria validated in this study and existing laboratory technology that flows as follows:  
1. If a GP requests LFTs in one of the standard electronic requesting systems, a simple box opens, 
asks if they want to screen for liver disease if results are abnormal. 
2. A positive response prompts the GP to enter data about patients’ alcohol consumption and 
BMI. 
3. In the laboratory if such a sample is detected to have an abnormality a cascade of additional 
aetiological tests will be performed and staging algorithms calculated.  
4. The diagnostic criteria are used to give a diagnosis and management plan ranging from 
management in general practice to referral for secondary care.  
5. In those where there is no definitive diagnosis, the GP is free to manage the patient as is 
standard practice now. 
6. All this data and information is passed back to the GP in a user friendly format, based within 
existing systems. 
This system is now the subject of an ongoing clinical trial. 
Conclusions 
This study suggested that over 35.6% of referrals could have been managed in primary care 
without a specialist opinion. The majority of this cohort were patients with NAFLD or ARLD and low 
fibrosis scores. For these patients we recommend primary care follow up with either a lifestyle 
intervention programme or an alcohol brief intervention. Information sheets detailing this advice are 
automatically sent to the referring primary care provider. Such a reduction in referral to secondary 
care services has the potential to dramatically reduce the referral rate, allowing more appropriate use 
of a limited resource. Additionally if the process was automated ensuring a higher rate of investigation 
of abnormal LFTs there would be capacity in the system to cope with this quality improvement. 
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